Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies

July 30th, 2014 Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that it has entered into an agreement with Gilead Sciences, Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV. These broadly neutralizing antibodies (bNAbs) were discovered in collaboration with the International …

Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies

Study Published in Immunity in Collaboration with The Scripps Research Institute and IAVI April 25, 2014 Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the publication of data in the May issue of Immunity regarding antibodies with significant potency and breadth against human immunodeficiency virus (HIV). The study, titled “Broadly neutralizing HIV antibodies define a novel glycan-dependent epitope on the …